ArticlePloS one2026
Best reference genes for unbiased normalized transcript expression in normal and dystrophic human cell models of myogenesis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LKB1 Dysregulation in Duchenne Muscular Dystrophy Models: Disease Specificity and Epigenetic Control by HDAC Inhibitors.Annals of the New York Academy of Sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-derived cell models of dystrophic myogenesis and differentiation are valuable preclinical tools for early and mutation-based assessment of candidate therapeutic approaches. Quantitative measurement of gene expression within such models plays a key role in these studies, but normalisation of RT-qPCR data requires a panel of validated stably expressed reference genes. This study aims to identify stable reference genes for RT-qPCR assays in three human derived muscle immortalized cell lines: one healthy WT (from a 16-year-old donor), and two dystrophic lines, DMD1 (from a 11-year-old patient carrying a stop codon mutation on exon 59) and DMD2, from a 14-year-old patient carrying an exon 48-50 deletion. We screened a pool of 14 candidate genes (ACTB, HPRT1, RPL13A, RPS18, GAPDH, ALAS1, UBC, YWHAZ, IPO8, PSMC4, HSP90AB1, NONO, CSNK2A2, AP3D1), investigating stability of expression from proliferation through to 11 days of myogenic differentiation. Data were analysed using four complementary approaches (Bestkeeper, geNorm, Normfinder and DeltaCt) to determine the most appropriate references both within and between cell lines. Our study shows that RPS18, UBC, YWHAZ scored highly across all comparisons, and we therefore suggest that these three genes represent an appropriate reference panel for these human myogenic cell lines, regardless of genotype or differentiation stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.